Novavax Bounce? Oversold Biotech with Licensing Upside and High Shorts
Novavax is a beaten-down vaccine specialist trading near oversold technicals and a sub-$1.3B enterprise value. Recent adjuvant licensing and sector momentum give a plausible re-rating catalyst over the next 45 trading days, but inconsistent revenue, cash burn, and heavy short interest make this a pragmatic, risk-managed trade.